A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells

• Benjamin J. Solomon ,

  Contributed equally to this work with: Benjamin J. Solomon, Jayesh Desai

  * E-mail: ben.solomon@petermac.org

  Affiliation Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

  ⨯
• Jayesh Desai ,

  Contributed equally to this work with: Benjamin J. Solomon, Jayesh Desai

  Affiliation Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

  ⨯
• Mark Rosenthal,

  Affiliation Medical Oncology, Royal Melbourne Hospital, Melbourne, Victoria, Australia

  ⨯
• Grant A. McArthur,

  Affiliation Department of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

  ⨯
• Scott T. Pattison,

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Stacey L. Pattison,

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Jennifer MacDiarmid,

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Himanshu Brahmbhatt ,

  ¶‡ These authors are joint senior authors on this work.

  Affiliation Cancer Therapeutics, EnGeneIC Ltd, Sydney, New South Wales, Australia

  ⨯
• Andrew M. Scott

  ¶‡ These authors are joint senior authors on this work.

  Affiliations Olivia Newton-John Cancer and Wellness Centre, Austin Hospital, Heidelberg, Victoria, Australia, Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Victoria, Australia

  ⨯